ReviewCardiovascular drugs and therapy2026
Crosstalk between Ryanodine Receptor 2 Dysfunction and FK506-Binding Proteins in Pulmonary Hypertension.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) is a complicated cardiovascular disorder marked by elevated pulmonary arterial pressure and vascular remodeling. The molecular interplay between Ryanodine Receptor 2 (RyR2) and FK506-binding protein 12.6 (FKBP12.6) emphasizes that their dissociation under hypoxic conditions results in intracellular calcium(Ca²⁺) dysregulation in pulmonary artery smooth muscle cells (PASMCs).
objectiveThis review article highlights important discoveries about how mitochondrial ROS, particularly those mediated by the Rieske iron-sulfur protein (RISP), trigger RyR2 activation and the sub sequent release of Ca2+. Furthermore, it covers a process that establishes a connection between sarcoplasmic reticulum calcium signaling, which promotes vasoconstriction and vascular remodeling, and mitochondrial dysfunction.
conclusionThe pathways involved inRyR2/FKBP12.6 destabilization lead to progression in PH. Moreover, targeting these pathways has been reported to be beneficial in PH management.
Indexed as
Identifiers
41389127What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.